Miller Keith L, Shafman Timothy D, Marks Lawrence B
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Semin Radiat Oncol. 2004 Oct;14(4):298-307. doi: 10.1016/j.semradonc.2004.06.004.
The risk of lung injury is a significant limiting factor in the use of thoracic radiotherapy for lung cancer. Given the high mortality and local failure rates in patients with unresectable lung cancer, a goal has been to increase the dose to the tumor as much as possible while trying to limit the damage to normal tissue. Efforts have been made to predict the risks for lung injury pretreatment, based on the planned dose and volume of lung treated, with mixed results. Complicating factors include performance status, underlying medical conditions, possible genetic predisposition to injury, and tumor location-associated changes in lung function. Much as a thoracic surgeon stratifies a patient's risk for pulmonary morbidity before resection, radiation oncologists should perform an assessment of patient specific factors that will impact on the potential toxicity of a given course of treatment. We present a proposed approach to the evaluation, risk assessment, and follow-up of patients treated with thoracic radiotherapy for lung cancer.
肺损伤风险是肺癌胸部放疗应用中的一个重要限制因素。鉴于不可切除肺癌患者的高死亡率和局部失败率,目标是在尽量限制对正常组织损伤的同时,尽可能提高肿瘤剂量。人们已努力根据计划的肺部照射剂量和体积在治疗前预测肺损伤风险,但结果不一。复杂因素包括身体状况、基础疾病、可能的损伤遗传易感性以及与肿瘤位置相关的肺功能变化。正如胸外科医生在切除术前对患者的肺部发病风险进行分层一样,放射肿瘤学家也应评估会影响特定疗程潜在毒性的患者个体因素。我们提出一种对接受肺癌胸部放疗患者进行评估、风险评估及随访的建议方法。